DPDoctor's PassportEducation
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
RapidMLAMSRAGP

ANCA, complement and extended autoantibodies

Essential points for quick revision.

!
Escalate

Pulmonary haemorrhage, rapidly declining kidney function, active urine sediment, mononeuritis multiplex, mesenteric ischaemia, myocarditis or threatened vision requires immediate specialist assessment. Draw relevant tests promptly, but do not delay organ-protective treatment or biopsy planning for antibody results.

Synopsis

Use ANCA, complement and extended autoantibodies to refine a clearly defined systemic phenotype, while prioritising tissue, urine and organ assessment and avoiding false reassurance or harm from indiscriminate panels.

  • ANCA testing is appropriate when small-vessel vasculitis is clinically plausible; it is not a general screen for fatigue, arthralgia or an isolated mildly raised CRP.
  • Interpret antigen-specific PR3-ANCA and MPO-ANCA with phenotype, urinalysis, renal function, chest findings, ENT disease, neuropathy and histology where feasible.
  • A positive ANCA can occur with infection, inflammatory bowel disease, autoimmune liver disease, medicines and other conditions, while ANCA-negative vasculitis remains possible.

Key red flags

Pulmonary–renal syndrome

Haemoptysis, falling haemoglobin, diffuse lung infiltrates, haematuria, proteinuria and rising creatinine indicate a medical emergency requiring parallel vasculitis and infection assessment.

Investigation priorities

01
PR3-ANCA and MPO-ANCAFirst step

Support classification of suspected ANCA-associated vasculitis within a compatible organ phenotype.

Management branches

Organ-threatening syndromeTest and treat in parallel

Pulmonary haemorrhage, glomerulonephritis, digital ischaemia, neuropathy, myocarditis or another rapidly progressive organ lesion.

  1. Stabilise physiology, obtain blood, urine, imaging and infection samples, and contact rheumatology plus the organ specialty immediately.
  2. Send PR3/MPO, complement and phenotype-directed serology while arranging biopsy; do not wait for the full panel when delay risks irreversible injury.
Open full textbook Answer 2 questions
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom